Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke
This article was originally published in The Pink Sheet Daily
Executive Summary
The fact alone that Rozerem is not a controlled substance doesn't "confer added safety" or superiority, DDMAC says.
You may also be interested in...
Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.
Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.
Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?
Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.